Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2 4Phase 1/2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Prostatic Neoplasms 2

Interventions

Cyclophosphamide 143pembrolizumab 127Nivolumab 116Carboplatin 99Dexamethasone 93Rituximab 91Paclitaxel 87Gemcitabine 85Lenalidomide 75Cytarabine 74Radiotherapy 73Cisplatin 70Bevacizumab 64Etoposide 62fludarabine phosphate 58fludarabine 56Ipilimumab 55Docetaxel 54Bortezomib 54Prednisone 49Doxorubicin 48Temozolomide 47Everolimus 46Erlotinib Hydrochloride 46Fluorouracil 44Azacitidine 44Capecitabine 43Calcium Dobesilate 43Filgrastim 42Melphalan 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Has results × orteronel × Clear all
NCT01084655 2019-07-30

Study of TAK-700 in Combination With Docetaxel and Prednisone in Men With Metastatic Castration-Resistant Prostate Cancer

Takeda

Phase 1/2 Completed
38 enrolled 29 charts
Genitourinary

Prostatic Neoplasms

NCT01666314 2018-03-20

Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer

Takeda

Phase 1/2 Completed
137 enrolled 41 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡